US2008220455A1PendingUtilityA1
p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR
Assignee: JAPAN PRESIDENT UNIV TOKYOPriority: Jul 19, 2001Filed: Apr 16, 2008Published: Sep 11, 2008
Est. expiryJul 19, 2021(expired)· nominal 20-yr term from priority
G01N 33/5008G01N 2510/00G01N 2500/00G01N 33/68C07K 16/18C07K 14/4747A61P 35/00C12Q 1/485A61P 43/00G01N 33/6875G01N 33/6842G01N 33/5011
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
p53-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a p53-induced nuclear protein that induces p53-dependent apoptosis by regulating p53 function through Ser 46 phosphorylation. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with p53-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating p53-mediated apoptosis.
Claims
exact text as granted — not AI-modified1 . An isolated DNA of the following (a) or (b):
(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NOs: 2 or 4, or (b) a DNA comprising the coding region of a nucleotide sequence of any one of SEQ ID NOs: 1, 3, and 5.
2 . An isolated DNA of the following (a) or (b) encoding a protein having the activity to induce apoptosis:
(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NOs: 2 or 4, wherein one or more amino acids are substituted, deleted, inserted, and/or added, or (b) a DNA hybridizing under stringent conditions to a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 1, 3, and 5.
3 . A DNA containing at least 15 nucleotides, wherein said DNA is complementary to a DNA comprising a nucleotide sequence of any one of SEQ ID NOs: 1, 3, and 5, or to the complementary strand thereof.
4 . An isolated protein encoded by the DNA of claim 1 or 2 .
5 . A vector comprising the DNA of claim 1 or 2 .
6 . A host cell carrying the DNA of claim 1 or 2 , or the vector of claim 5 .
7 . A method for producing the protein of claim 4 , wherein said method comprises the steps of culturing the host cell of claim 6 , and recovering the protein expressed by said host cell.
8 . An antibody binding to the protein of claim 4 .
9 . An antisense polynucleotide to the DNA comprising a nucleotide sequence of any one of SEQ ID NOs: 1, 3, and 5.
10 . A method of screening for a candidate compound for an apoptosis-regulating agent, wherein said method comprises the steps of:
(a) contacting a test sample with the protein of claim 4 , (b) detecting the binding activity of the test sample to said protein, and (c) selecting a compound having the activity to bind to said protein.
11 . A method of screening for a candidate compound for an apoptosis-regulating agent, wherein said method comprises the steps of:
(a) contacting a test sample with the protein of claim 4 in the presence of p53, (b) measuring the phosphorylation level of said p53 protein at the Ser46 residue after the contact, and (c) selecting a compound capable of regulating apoptosis based on the phosphorylation level measured in step (b).
12 . A method of screening for a candidate compound for an apoptosis-regulating agent, wherein said method comprises the steps of:
(a) contacting a test sample with a cell containing a vector having the structure in which the p53-binding sequence of SEQ ID No: 8 and a reporter gene are operably linked, or an extract of said cell, (b) measuring the expression level of said reporter gene, and (c) selecting a compound capable of decreasing or increasing the expression level of said reporter gene measured in step (b), compared to that measured in the absence of the test sample.
13 . An apoptosis-regulating agent comprising as an effective ingredient a compound selected by a method of any one of claims 10 to 12 .Join the waitlist — get patent alerts
Track US2008220455A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.